- Asia Pacific
- South Africa
- Hong Kong
- New Zealand
- Czech Republic
- United Kingdom
Recent Pfizer Press Releases
4/9/07 9:58 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a webcast of a conference call with investment analysts at 12 Noon EDST on Friday, April 20. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2007 Performance Report, to be issued that morning. To listen to the webcast and view the Performance Report, visit our web site homepagemore...
Pharmacia Subsidiaries Reach $34.7 Million Settlement with DOJ; Resolve Allegations of Improper Activities Prior to Acquisition by Pfizer4/2/07 1:38 pm EDT
Pfizer Discovered and Promptly Reported Subsidiary’s Off-Label Marketing of Genotropin to Justice Department, Other AgenciesNEW YORK--(BUSINESS WIRE)--Pfizer announced today that two subsidiaries of Pharmacia have reached separate settlements with the United States Department of Justice to address charges stemming from the off-label marketing of Genotropin — a human growth hormone medicine — and the inappropriate use of a vendor contract to increase the sales of other Pharmacia medicines. Both settlements cover activities that occurred at Pharmacia before thatmore...
Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show3/27/07 1:20 pm EDT
Patients Who Took Lipitor Had Fewer Cardiovascular Events and Lower Hospitalization Costs Compared with Patients Who Took Simvastatin in the IDEAL StudyNEW ORLEANS--(BUSINESS WIRE)--Pfizer announced today that Lipitor® (atorvastatin calcium) Tablets (80 mg) lowered hospitalization costs by significantly reducing the risk of cardiovascular events in patients with heart disease, according to two separate economic analyses. The data were presented at the annual meeting of the American College of Cardiology. “One of these analyses suggests that even with the availability of lowmore...
Lipitor Provides Unprecedented Cardiovascular Risk Reductions in Diabetes Patients with Metabolic Syndrome and in Stroke Patients3/26/07 4:30 pm EDT
Lipitor is the Only Statin to Have Been Studied Solely in Patients with Recent Stroke or Mini-strokeNEW ORLEANS--(BUSINESS WIRE)--Pfizer announced today that Lipitor® (atorvastatin calcium) Tablets 10 mg provided a significant 61 percent reduction in stroke in patients with type 2 diabetes and metabolic syndrome but without heart disease. In a separate study, patients who had suffered a recurrent stroke or mini-stroke during the trial had a significant 53 percent reduction in the risk of major coronary events (death from cardiac causes, heartmore...
3/26/07 11:27 am EDT
New Results Build on Previous Data that Lipitor is the Only Statin to Show an Impact in Head-To-Head Imaging Trials
Separate Analysis Shows Lipitor Cuts the Risk of Coronary Events by Half in Recurrent Stroke PatientsNEW ORLEANS--(BUSINESS WIRE)--Pfizer said today that results from two new imaging trials showed that higher dose Lipitor stopped the progression of atherosclerosis in patients with coronary heart disease or familial hypercholesterolemia (FH). The trials, which were designed to investigate the efficacy of the former investigational compound torcetrapib in combination with Lipitor compared to Lipitor alone, were presented today at the annual meeting ofmore...
3/23/07 5:01 pm EDTNEW YORK--(BUSINESS WIRE)--In response to an announcement today by Mylan Laboratories that it has launched a generic competitor to Norvasc, Pfizer said it is making available its own generic amlodipine besylate product immediately through the company’s Greenstone subsidiary. Norvasc also will remain available to patients. Pfizer said it will continue to pursue all available legal remedies to protect the market for Norvasc through a six-more...
Pfizer to Present New Lipitor Data, Including Results from Three Large Atherosclerosis Imaging Trials, at the American College of Cardiology Meeting3/23/07 10:14 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer announced today that new data regarding the effect of Lipitor (atorvastatin calcium) on atherosclerosis, cardiovascular events such as heart attacks and strokes, and health economics will be presented next week at the American College of Cardiology annual meeting in New Orleans. Atherosclerosis Imaging Trials Three large imaging studies compared Pfizer’s former investigational compoundmore...
3/22/07 1:59 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Court of Appeals for the Federal Circuit has issued a decision reversing a lower court ruling upholding the company’s U.S. patent covering amlodipine besylate, the active ingredient in Norvasc. Pfizer is reviewing the decision and is considering all its options, including seeking reconsideration. Generic manufacturer Apotex filed the appeal after a lowermore...
3/20/07 3:36 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that a federal court in the District of New Jersey (Newark) has upheld the three main U.S. patents covering Celebrex, the company’s selective non-steroidal anti-inflammatory (NSAID) medicine used to treat pain and inflammation. The patents had been challenged by generic manufacturer Teva Pharmaceuticals USA. Judge John C. Lifland ruled that the patents (Nos. 5,466,823; 5,563,165more...